Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medeva PLC -- Ignore unavailable to you. Want to Upgrade?

To: Mr Bond who wrote (1)	5/15/1998 11:19:00 PM
From: Dayuhan	Respond to of 9

Thanks for the input. I'm not sure that American biotech companies are sensibly valued. There are an amazing number of companies in this sector with no products and no revenues, hanging on FDA approval and trading at pretty outrageous prices. That's why Medeva caught my eye - it actually seemed to be earning, which in this sector and price level is pretty rare. I understand about the tarred-with-the-same-brush syndrome, but have you heard anything about the company itself which could have caused the recent slump? I know the fen/phen problem might have something to do with it, but Ionamin is not the company's only product, and the strong potential of the Aviron/Medeva flu vaccine would seem to offset this. Again, is there something I'm missing? In any event, I don't expect immediate movement, so I guess I have time to think it over - although I've said that before, and lived to regret it. We'll see. Steve